Featured Press Releases

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

Aptar Pharma signs an exclusive agreement with Pulmotree to develop and promote the Kolibri™ non-propellant liquid inhaler platform

LabConnect and Australian Clinical Labs

LabConnect and Australian Clinical Labs' Specialised Trials Announce a Strategic Partnership in the Australia and Asia Pacific Region

  • 23 Feb 2025

LabConnect and Australian Clinical Labs' (ACL) Specialised Trials have forged a strategic...

MM+M honors Petauri

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 Begins with First Patient Dosed

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

MTF Biologics and Kolosis BIO introduce Summit Matrix™, expanding solutions for orthopedic and spinal surgeries

MTF Biologics and Kolosis BIO introduce Summit Matrix™, expanding solutions for orthopedic and spinal surgeries

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

  • Bayer
  • 15 Jun 2026
EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

  • The EVERY Company
  • 15 Jun 2026
Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

  • Incyte
  • 15 Jun 2026
AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

  • AbbVie
  • 12 Jun 2026
Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.